Brandon May

Brandon May is a freelance medical writer and owner of May Medical Communications, LLC. He holds a BS in Nutrition and Dietetics from the University of Houston. Throughout his career, he has written over 700 medical news articles across several different therapeutic areas. In addition to covering the medical news, Brandon also creates content for continuing medical education providers, hospitals, and pharmaceutical and medical device companies across the globe.

All articles by Brandon May

Type 2 Diabetes

Approaches to Reduce Therapeutic Inertia in Diabetes Management

Brandon May

July 30, 2021

A team of researchers investigated the effect of interventions to overcome therapeutic inertia regarding glycemic control in patients with type 2 diabetes.

Cardiovascular and Metabolic Disorders

Women Are Under-Represented in Acute Stroke Trials

Brandon May

June 22, 2021

This meta-analysis included patients with stroke and/or transient ischemic attacks to determine whether women are under-represented in clinical trials of acute stroke therapies.

Obesity

Bariatric Surgery Reduces ICP in Women With Obesity and Intracranial Hypertension

Brandon May

June 18, 2021

Investigators compared bariatric surgery with a community weight management intervention in ability to reduce intracranial pressure among patients with idiopathic intracranial hypertension.

Obesity

Interplay of Vitamin D Deficiency and BMI in Patients With Acne

Brandon May

June 10, 2021

The effects of serum 25(OH)D3 levels and BMI on acne and their relationship to acne severity is examined.

General Endocrinology

Oral and Gut Microbial Diversity Offers Diagnostic, Prognostic COVID-19 Insight

Brandon May

June 4, 2021

Researchers investigated the potential use of the microbiome as a non-invasive biomarker for COVID-19 diagnosis and prognosis.

Type 1 Diabetes

Dasiglucagon Rapidly Restores Plasma Glucose in Children With Insulin-Induced Hypoglycemia

Brandon May

May 27, 2021

The researchers’ objective was to evaluate the safety and efficacy of dasiglucagon in patients aged 6 to 17 years with type 1 diabetes.

Type 2 Diabetes

Canagliflozin May Not Reduce Myocardial Infarction Risk in Patients With Type 2 Diabetes

Brandon May

May 12, 2021

Treatment with canagliflozin may not significantly lower risk for myocardial infarction among patients with type 2 diabetes and comorbid chronic kidney disease or among patients with diabetes who have a history of or have a high risk for CVD.

Cardiovascular and Metabolic Disorders

Should the Framingham Risk Score Include HDL Anti-Inflammatory Capacity?

Brandon May

May 6, 2021

This nested case-control study included more than 300 patients from the PREVEND study who experienced a first CV event.

General Endocrinology

New Guidance: American College of Physicians Discusses Antibody Response in COVID-19 Immunity

Brandon May

May 5, 2021

To help clinicians and patients determine if antibodies protect against reinfection, the ACP discussed tests for diagnosing and estimating the prevalence of COVID-19.

This PD-1 inhibitor is effective for treating melanoma, though it can be highly toxic and there is a

General Endocrinology

Does Autoimmune Disease Affect AE Rate With Immune Checkpoint Inhibition for Melanoma?

Brandon May

May 3, 2021

The safety and efficacy of immune checkpoint inhibition in patients with advanced melanoma with and without autoimmune disease was assessed.

Next post in General Endocrinology